International review of blood donation screening for anti-HBc and occult hepatitis B virus infection.
HBV screening
NAT
anti‐HBc testing
blood transfusion
safety
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
revised:
13
08
2024
received:
27
04
2024
accepted:
08
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
3
10
2024
Statut:
aheadofprint
Résumé
Hepatitis B core antibody (anti-HBc) screening has been implemented in many blood establishments to help prevent transmission of hepatitis B virus (HBV), including from donors with occult HBV infection (OBI). We review HBV screening algorithms across blood establishments globally and their potential effectiveness in reducing transmission risk. A questionnaire on HBV screening and follow-up strategies was distributed to members of the International Society of Blood Transfusion working party on transfusion-transmitted infectious diseases. Screening data from 2022 were assimilated and analyzed. A total of 30 unique responses were received from 25 countries. Sixteen respondents screened all donations for anti-HBc, with 14 also screening all donations for HBV DNA. Anti-HBc prevalence was 0.42% in all blood donors and 1.19% in new donors in low-endemic countries; however, only 44% of respondents performed additional anti-HBc testing to exclude false reactivity. 0.68% of anti-HBc positive, HBsAg-negative donors had detectable HBV DNA. Ten respondents did universal HBV DNA screening without anti-HBc, whereas four respondents did not screen for either. Deferral strategies for anti-HBc positive donors were highly variable. One transfusion-transmission from an anti-HBc negative donor was reported. Anti-HBc screening identifies donors with OBI but also results in the unnecessary deferral of a significant number of donors with resolved HBV infection and donors with false-reactive anti-HBc results. Whilst confirmation of anti-HBc results could be improved to reduce donor deferral, transmission risks associated with anti-HBc negative OBI donors must be considered. In high-endemic areas, highly sensitive HBV DNA testing is required to identify infectious donors.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B core antibody (anti-HBc) screening has been implemented in many blood establishments to help prevent transmission of hepatitis B virus (HBV), including from donors with occult HBV infection (OBI). We review HBV screening algorithms across blood establishments globally and their potential effectiveness in reducing transmission risk.
MATERIALS AND METHODS
METHODS
A questionnaire on HBV screening and follow-up strategies was distributed to members of the International Society of Blood Transfusion working party on transfusion-transmitted infectious diseases. Screening data from 2022 were assimilated and analyzed.
RESULTS
RESULTS
A total of 30 unique responses were received from 25 countries. Sixteen respondents screened all donations for anti-HBc, with 14 also screening all donations for HBV DNA. Anti-HBc prevalence was 0.42% in all blood donors and 1.19% in new donors in low-endemic countries; however, only 44% of respondents performed additional anti-HBc testing to exclude false reactivity. 0.68% of anti-HBc positive, HBsAg-negative donors had detectable HBV DNA. Ten respondents did universal HBV DNA screening without anti-HBc, whereas four respondents did not screen for either. Deferral strategies for anti-HBc positive donors were highly variable. One transfusion-transmission from an anti-HBc negative donor was reported.
DISCUSSION
CONCLUSIONS
Anti-HBc screening identifies donors with OBI but also results in the unnecessary deferral of a significant number of donors with resolved HBV infection and donors with false-reactive anti-HBc results. Whilst confirmation of anti-HBc results could be improved to reduce donor deferral, transmission risks associated with anti-HBc negative OBI donors must be considered. In high-endemic areas, highly sensitive HBV DNA testing is required to identify infectious donors.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Institute for Health and Care Research
ID : NIHR203338
Informations de copyright
© 2024 The Author(s). Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
Hollinger FB, Dodd RY. Hepatitis B virus traceback and lookback: factors to consider. Transfusion. 2009;49(1):176–184. https://doi.org/10.1111/J.1537-2995.2008.01961.X
Candotti D, Assennato SM, Laperche S, Allain JP, Levicnik‐Stezinar S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut. 2019;68(2):313–321. https://doi.org/10.1136/GUTJNL-2018-316490
Harvala H, Reynolds C, Gibney Z, Derrick J, Ijaz S, Davison KL, et al. Hepatitis B infections among blood donors in England between 2009 and 2018: is an occult hepatitis B infection a risk for blood safety? Transfusion. 2021;61(8):2402–2413. https://doi.org/10.1111/TRF.16543
Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71(2):397–408. https://doi.org/10.1016/J.JHEP.2019.03.034
Lelie N, Busch M, Kleinman S. Residual risk of transfusion‐transmitted hepatitis B virus (TT‐HBV) infection by NAT‐screened blood components: a review of observed versus modeled infectivity from donors with window period and occult HBV infections. Transfusion. 2021;61(11):3190–3201. https://doi.org/10.1111/TRF.16675
Spreafico M, Berzuini A, Foglieni B, Candotti D, Raffaele L, Guarnori I, et al. Poor efficacy of nucleic acid testing in identifying occult HBV infection and consequences for safety of blood supply in Italy. J Hepatol. 2015;63(5):1068–1076. https://doi.org/10.1016/J.JHEP.2015.06.016
Seed CR, Allain JP, Lozano M, Laperche S, Gallian P, Gross S, et al. International forum on occult hepatitis B infection and transfusion safety. Vox Sang. 2019;114(4):e1–e35. https://doi.org/10.1111/VOX.12743
Juhl D, Knobloch JKM, Görg S, Hennig H. Comparison of two test strategies for clarification of reactive results for anti‐HBc in blood donors. Transfus Med Hemother. 2016;43(1):37–43. https://doi.org/10.1159/000441676
Fu MX, Ingram J, Roberts C, Nurmi V, Watkins E, Dempsey N, et al. Blood donation screening for hepatitis B virus core antibodies: the importance of confirmatory testing and initial implication for rare blood donor groups. Vox Sang. 2024;119:447–459. https://doi.org/10.1111/VOX.13608
Fu MX, Simmonds P, Andersson M, Harvala H. Biomarkers of transfusion transmitted occult hepatitis B virus infection: where are we and what next? Rev Med Virol. 2024;34(2):e2525. https://doi.org/10.1002/RMV.2525
Im YR, Jagdish R, Leith D, Kim JU, Yoshida K, Majid A, et al. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2022;7(10):932–942. https://doi.org/10.1016/S2468-1253(22)00201-1
GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796–829. https://doi.org/10.1016/S2468-1253(22)00124-8
Satake M, Yamagishi N, Tanaka A, Goto N, Sakamoto T, Yanagino Y, et al. Transfusion‐transmitted HBV infection with isolated anti‐HBs‐positive blood. Transfusion. 2023;63(6):1250–1254. https://doi.org/10.1111/TRF.17390
Narayan S, Poles D, Bellamy M, Spinks C, Mistry H, Carter‐Graham S. On behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2022 Annual SHOT Report. 2023 https://doi.org/10.57911/wz85-3885
NHS Blood and Transplant. Introducing selective screening for hepatitis B anti‐core (anti‐HBc) to reduce the risk of occult hepatitis B—hospitals and science—NHSBT. Available from: https://hospital.blood.co.uk/the-update/introducing-selective-screening-for-hepatitis-b-anti-core-anti-hbc-to-reduce-the-risk-of-occult-hepatitis-b/
Tanaka A, Yamagishi N, Hasegawa T, Miyakawa K, Goto N, Matsubayashi K, et al. Marked reduction in the incidence of transfusion‐transmitted hepatitis B virus infection after the introduction of antibody to hepatitis B core antigen and individual donation nucleic acid amplification screening in Japan. Transfusion. 2023;63(11):2083–2097. https://doi.org/10.1111/TRF.17546
Vermeulen M, Dickens C, Lelie N, Walker E, Coleman C, Keyter M, et al. Hepatitis B virus transmission by blood transfusion during 4 years of individual‐donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion. 2012;52(4):880–892. https://doi.org/10.1111/J.1537-2995.2011.03355.X
McCullough J, Alter HJ, Ness PM. Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy. Transfusion. 2019;59(3):1132–1146. https://doi.org/10.1111/TRF.15103
Russell WA, Owusu‐Ofori S, Owusu‐Ofori A, Micah E, Norman B, Custer B. Cost‐effectiveness and budget impact of whole blood pathogen reduction in Ghana. Transfusion. 2021;61(12):3402–3412. https://doi.org/10.1111/TRF.16704
Escolar G, Diaz‐Ricart M, McCullough J. Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: an updated view during a pandemic. Transfusion. 2022;62(1):227–246. https://doi.org/10.1111/TRF.16747
Lelie N, Bruhn R, Busch M, Vermeulen M, Tsoi WC, Kleinman S, et al. Detection of different categories of hepatitis B virus (HBV) infection in a multi‐regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV‐DNA testing. Transfusion. 2017;57(1):24–35. https://doi.org/10.1111/TRF.13819
Candotti D, Lin CK, Belkhiri D, Sakuldamrongpanich T, Biswas S, Lin S, et al. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence. Gut. 2012;61(12):1744–1753. https://doi.org/10.1136/GUTJNL‐2011‐301281
Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol. 2006;36(Suppl 1):S33–S44. https://doi.org/10.1016/S1386-6532(06)80007-7
World Health Organization. Global Hepatitis Report 2017. 2017. Available from: https://iris.who.int/bitstream/handle/10665/255016/9789241565455-eng.pdf?sequence=1
Blank L, Baxter S, Woods HB, Goyder E, Lee A, Payne N, et al. What is the evidence on interventions to manage referral from primary to specialist non‐emergency care? A systematic review and logic model synthesis. Health Serv Deliv Res. 2015;3(24):1–430. https://doi.org/10.3310/HSDR03240
Faddy HM, Osiowy C, Custer B, Busch M, Stramer SL, Adesina O, et al. International review of blood donation nucleic acid amplification testing. Vox Sang. 2024;119(4):315–325. https://doi.org/10.1111/VOX.13592
Fu MX, Simmonds P, Andreani J, Baklan H, Webster M, Asadi R, et al. Ultrasensitive PCR system for HBV DNA detection: risk stratification for occult hepatitis B virus infection in English blood donors. J Med Virol. 2023;95(10):e29144. https://doi.org/10.1002/JMV.29144